Collplant Biotechnologies Ltd Stock Price, News & Analysis

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open. The company, known for its innovative non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics, will provide updates on its financial performance.

CollPlant Biotechnologies (NASDAQ:CLGN) has appointed Bowman Bagley as Vice President, Commercial North America in a newly created position. Bagley, who previously served as VP at Wasatch Biolabs and CEO at Advanced BioMatrix, will lead the company's commercial strategy and execution in North America.

The appointment aligns with CollPlant's growth strategy for its non-animal-derived recombinant human collagen (rhCollagen) technology. Bagley will oversee sales, marketing, logistics, and market expansion for CollPlant's rhCollagen-based products and platforms, particularly focusing on bioinks portfolio growth and research market sales.

Bagley brings extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering, along with a track record in sales, product development, and licensing. He holds a B.S. in Neuroscience and an MBA from the University of Utah.

CollPlant Biotechnologies (NASDAQ: CLGN) has expanded its partnership with STEMCELL Technologies to extend the use of CollPlant's proprietary rhCollagen beyond research applications into clinical development and commercial-scale manufacturing. The company's plant-derived, Type I recombinant human collagen technology is positioned as a safer, more sustainable alternative to animal-sourced materials. This expansion reflects market evolution and growing industry demand for ethically sourced, consistent materials in regenerative medicine, tissue regeneration, and medical aesthetics applications.

CollPlant Biotechnologies (CLGN) has secured a European patent allowance for its collagen-based formulations used in soft tissue fillers and implants. The patent, valid until 2041, covers injectable fillers and regenerative breast implant technology based on their proprietary recombinant human collagen (rhCollagen). The protected technology includes a 3D biocompatible and degradable soft tissue implant with a bioprinted scaffold and injectable filler. This development strengthens CollPlant's position in the aesthetic and reconstructive markets, with the injectable soft-tissue filler market valued at over $6 billion and the breast implant market estimated at over $3 billion.

CollPlant Biotechnologies (NASDAQ: CLGN) has announced a $3.6 million registered direct offering priced at-the-market, selling 1,200,002 ordinary shares at $3.00 per share. The company will also issue unregistered warrants to purchase up to 1,200,002 ordinary shares at a $3.00 exercise price in a concurrent private placement. The warrants will be exercisable immediately with a 3.5-year term. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support general corporate purposes, including collaboration with AbbVie on dermal filler development, working capital, and R&D programs. The offering is expected to close around June 2, 2025.

CollPlant Biotechnologies (NASDAQ: CLGN) reported Q1 2025 financial results and corporate updates. The company received a $2 million milestone payment from AbbVie in February 2025. Q1 revenues were $2.1 million, up from $98,000 in Q1 2024, with a net loss of $1.5 million. Cash position stood at $10.7 million as of March 31, 2025. The company continues advancing its regenerative breast implant program, with successful 3D bioprinting of 200cc commercial-size implants and encouraging preclinical results. CollPlant implemented a cost-cutting plan, reducing workforce by 20%, extending runway through Q2 2026. The company is also progressing with its photocurable dermal filler program and expanding distribution of Vergenix STR across Europe and Asia. Notable developments include new patents in Japan for rhCollagen curable BioInks and expansion of their intellectual property portfolio.

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine with a focus on non-animal-derived rhCollagen technology, has announced it will release its first quarter 2025 financial results on Wednesday, May 28, 2025, before U.S. markets open. The company develops innovative technologies and products for tissue regeneration and medical aesthetics applications.

CollPlant Biotechnologies (NASDAQ: CLGN) has positioned its Collink.3D® BioInks as a solution aligned with the FDA's recent announcement to phase out animal testing requirements for drug development. The company's rhCollagen-based BioInk products can be used to create tissue-on-a-chip and organ-on-a-chip systems, offering alternatives to traditional animal testing methods.

These innovative systems can help bridge the gap between laboratory studies and clinical trials while being more cost-effective and reducing time to market. CollPlant has also developed Computational Modeling and Simulation (CM&S) methodologies for their regenerative breast implant development, enabling precise prediction of implant behavior and tissue interaction without animal studies.

CollPlant Biotechnologies (CLGN) reported its 2024 financial results and corporate updates, highlighting progress in its regenerative breast implant program targeting a $3 billion market opportunity. The company received a $2 million development payment from AbbVie in February 2025.

Key financial results for 2024 include: revenues of $515,000 (down from $11.0 million in 2023), net loss of $16.6 million ($1.45 per share), and cash position of $11.9 million as of December 31, 2024. The company implemented a 20% workforce reduction to extend operations through Q2 2026.

Notable developments include: successful printing of 200cc commercial-sized breast implants, promising six-month study data showing vascularization and tissue ingrowth, expansion of Vergenix STR distribution in Europe and Asia, and new patent grants in Japan for rhCollagen curable BioInks and in the US for photocurable dermal filler technology.